Şunu aradınız:: ufh (İngilizce - Slovakça)

ufh/ enox
ufh/ enox +gpiib/ iiia

ufh goods,
ufh goods,

arm a ufh/enox
rameno a ufh/enox

bivalirudin +gpiib/ iiia ufh/ enox
+gpiib/ iiia

ufh/enox1 + gp iib/iiia inhibitor (%)
ufh/enox1 + inhibítor gp iib/iiia (%)

the baseline characteristics and duration of fondaparinux treatment were comparable in both ufh groups.
východiskové charakteristiky a dĺžka liečby fondaparínom boli v oboch skupinách s ufh porovnateľné.

d last dose of fondaparinux, the median dose of ufh was 8000 iu and the incidence of major bleeding
u pacientov, ktorí podstúpili

10 in arm a of the acuity trial, ufh or enoxaparin was administered in accordance with the relevant guidelines for the management of acs in patients with ua and nstemi.
pacienti v ramene a a b boli randomizovaní aj na

patients could have been pre-treated with ufh during the screening phase but patients treated for more than 24 hours with therapeutic dose of anticoagulant or with uncontrolled hypertension were ed
fondaparín 5 mg (pre telesnú hmotnosť 100 kg) podávaný s. c. jedenkrát denne sa porovnával

randomised patients could have been pre-treated with ufh during the screening phase but patients treated for more than 24 hours with therapeutic dose of anticoagulant or with uncontrolled hypertension were excluded.
randomizovaní pacienti mohli byť predliečení s ufh počas skríningovej fázy, ale pacienti liečení viac ako 24 hodín terapeutickou dávkou antikoagulancia alebo s nekontrolovanou hypertenziou boli vylúčení.

the recommended regimen of ufh in the treatment of pe were 5.5%, 6.6% and 7.4%, respectively.
3,6 % a 8,3 %, zatiaľ čo výskyt u pacientov dostávajúcich odporučené dávkovanie ufh v liečbe pe bol 5,5 %, 6,6 % a 7,4 %.